Development of tumor-targeting cell therapeutics for cancer therapy.
| Project/Area Number |
15K18850
|
|---|
| Research Category |
Grant-in-Aid for Young Scientists (B)
|
| Allocation Type | Multi-year Fund |
|---|
| Research Field |
Physical pharmacy
|
|---|
| Research Institution | Kyoto Pharmaceutical University |
|---|
Principal Investigator |
|
|---|
| Project Period (FY) |
2015-04-01 – 2017-03-31
|
| Project Status |
Completed (Fiscal Year 2016)
|
| Budget Amount *help |
¥4,030,000 (Direct Cost: ¥3,100,000、Indirect Cost: ¥930,000)
Fiscal Year 2016: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
Fiscal Year 2015: ¥2,210,000 (Direct Cost: ¥1,700,000、Indirect Cost: ¥510,000)
|
|---|
| Keywords | 細胞移植治療 / 間葉系幹細胞 / 細胞機能化 / がん治療 / 細胞治療 / アビジン－ビオチン法 / 遺伝子導入法 |
|---|
| Outline of Final Research Achievements |
In the present study, we tried to develop tumor-targeting cell therapeutics for cancer therapy using mesenchymal stem cells (MSCs), which have a tumor-homing ability. We selected an avidin-biotin complex (ABC) method and a gene transfection method to functionalize mouse mesenchymal stem cell line C3H10T1/2 cells. We revealed the ABC method could modify C3H10T1/2 cells with Nanoluc luciferase, a reporter protein, for at least 14 days without significant changes in the characteristics of C3H10T1/2 cells. The ABC method was also used to develop doxorubicin-containing liposome-modified C3H10T1/2 cells. Moreover, interferon gamma-releasing C3H10T1/2 cells were established by the gene transfection method. These cells showed an excellent anti-tumor effects. These functionalized MSCs will be useful for cell-based cancer therapy.
|
Report
(3 results)
Research Products
(6 results)
